Innoviva Inc (INVA)

12.58
OTC : Health Care
Prev Close 12.58
Day Low/High 0.00 / 0.00
52 Wk Low/High 8.67 / 14.55
Avg Volume 1.19M
Exchange OTC
Shares Outstanding 109.35M
Market Cap 1.43B
EPS 0.50
P/E Ratio 20.50
Div & Yield N.A. (N.A)

Latest News

Innoviva To Participate In Bank Of America Merrill Lynch Healthcare Conference On May 17

Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W.

Relvar Ellipta Significantly Improved Asthma Control In Salford Lung Study Patients Compared With Their Usual Care

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva Inc (NASDAQ: INVA) today announced positive results from the innovative Salford Lung Study (SLS) in asthma, carried out amongst 4,233 patients treated by their own General...

Innoviva Reports First Quarter 2017 Financial Results

Innoviva, Inc. (NASDAQ: INVA) today reported financial results for the first quarter of 2017.

Short Interest In Innoviva Falls 51.5%

The most recent short interest data has been released for the 04/13/2017 settlement date, which shows a 9,926,546 share decrease in total short interest for Innoviva Inc , to 9,337,021, a decrease of 51.53% since 03/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Innoviva To Report First Quarter Financial Results On April 27 At 5:00 P.m. EDT

Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the first quarter ended March 31, 2017 after market close on Thursday, April 27, 2017.

Sarissa Lawsuit Likely After Innoviva Claims Win Over Dissidents

Sarissa Lawsuit Likely After Innoviva Claims Win Over Dissidents

Sarissa was seeking election of three nominees at the pharmaceutical company that the activist claims is being run for management's benefit.

Innoviva Announces Preliminary Results Of Annual Meeting

Innoviva, Inc. (the "Company" or "Innoviva") (NASDAQ: INVA) is pleased to announce that, based on the advice of its proxy solicitor, the Company believes shareholders voted to reelect all seven of Innoviva's director...

Innoviva Urges Shareholders To Vote "FOR" All Of Innoviva's Value-Creating Directors On The WHITE Proxy Card TODAY

Innoviva, Inc. (the "Company" or "Innoviva") (NASDAQ: INVA) today called upon shareholders to make the clear choice to vote FOR the Company's Board of Directors (the "Board").

Innoviva Issues Statement On Upcoming Annual Meeting Of Stockholders

Innoviva, Inc. (the "Company" or "Innoviva") (NASDAQ: INVA) today summarized for shareholders the clear and compelling reasons to vote FOR its nominees at the Company's upcoming Annual Meeting of Stockholders to be held on...

Sarissa Urges Shareholders To See Through Innoviva's Last Minute Flip-Flop On Cost Cuts; Notes Conspicuous Absence Of Promises To Fix Bad Corporate Governance

GSK SHOULD SEEK SARISSA'S OPINION ON INNOVIVA; GSK SHOULD NOT DECIDE HOW TO VOTE BEFORE HEARING SARISSA'S SIDE

With Strong And Consistent Growth In Profits, Innoviva Has Been Able To Deliver Increasing Returns To Shareholders - Including Capital Returns Of More Than $210 Million To Investors Since The First Quarter Of 2015. (Graphic: Business Wire)

Innoviva, Inc. (the "Company" or "Innoviva") (NASDAQ: INVA) today announced its Board of Directors has issued the following letter to shareholders in connection with the upcoming Annual Meeting of Stockholders to be held on...

Innoviva To Undertake Comprehensive Review Of Its Cost And Executive Compensation Structures

Innoviva, Inc. (the "Company" or "Innoviva") (NASDAQ: INVA) issued the following statement ahead of its upcoming Annual Meeting of Stockholders to be held on April 20, 2017: Innoviva strives to engage with all of...

Sarissa Capital Files Presentation In Proxy Contest With Innoviva

Sarissa believes Innoviva directors have breached their fiduciary duties by overpaying executives and overpaying themselves

Egan-Jones Supports All Three Sarissa Capital Nominees For Innoviva Board

All three proxy governance firms support Sarissa Capital and recommend Innoviva shareholders VOTE ON THE GOLD CARD

Sarissa Capital Is Concerned That Innoviva Will Waste Shareholder Money On Imprudent Acquisitions

Sarissa Capital is worried that acquisitions by Innoviva will irreparably destroy shareholder value

Sarissa Capital Compelled To Clarify Egregious Misstatements Made By Innoviva

ISS and Glass Lewis both recommend that Innoviva shareholders vote on Sarissa's GOLD PROXY CARD

Innoviva Comments On ISS And Glass Lewis Reports

Innoviva, Inc. (the "Company" or "Innoviva") (NASDAQ:INVA) today commented on reports issued by Institutional Shareholder Services ("ISS") and Glass, Lewis & Co.

ISS Supports All Three Sarissa Capital Nominees For Innoviva Board

ISS recommends that Innoviva shareholders vote on Sarissa's GOLD PROXY CARD FOR George Bickerstaff, Jules Haimovitz and Odysseas Kostas

Innoviva Announces $50 Million Partial Royalty Notes Redemption

Innoviva, Inc. (the "Company" or "Innoviva") (Nasdaq: INVA) today announced that on May 15, 2017, the next interest payment date under its non-recourse royalty notes due 2029 (the "Royalty Notes"), Innoviva will prepay $50...

Glass Lewis Supports Sarissa Capital's Nominees For Innoviva Board

Glass Lewis recommends that shareholders vote on Sarissa's GOLD PROXY CARD for GEORGE BICKERSTAFF and ODYSSEAS KOSTAS

Sarissa Capital Believes That Innoviva's Recent Statements Reinforce That Innoviva Is Being Run For The Benefit Of Management And Not Shareholders

Innoviva pays its employees and directors nearly $16 million a year primarily to monitor an agreement that gives Innoviva very little input and no control

Newman Ferrara LLP Announces Corporate Governance Investigation Of Innoviva, Inc. - INVA

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Innoviva, Inc.